About us

Energenesis Biomedical (TWO: 6657) was awarded one of the "TOP Wound Care Solution Providers" by MED TECH OUTLOOK.

It is announced and detailed by the October 2020 Issue. We are proud that so far our achievement on developing the prescription drug to be indicated for diabetic foot ulcer (DFU), whose phase II study has been completed, is recognized.